Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial

Published:2024-09 Issue: Volume: Page:
ISSN:2667-100X
Container-title:Journal of Intensive Medicine
language:en
Short-container-title:Journal of Intensive Medicine

Author:

Chavez-Tapia Norberto,Sayeed Muneeba Ahsan,Luxmi Shobha,Kasper Douglas J.,Xue Fenchao,Shen Yang^ORCID,Fan Weiliang^ORCID,Yuan Wei,Du Bin^ORCID

Publisher

Elsevier BV

Reference32 articles.

1. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N Engl J Med,2020

2. Severe COVID-19;Berlin;N Engl J Med,2020

3. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention;Wu;JAMA,2020

4. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda (MD): National Institutes of Health (US)

5. 2021 Apr 21-2024 Feb 29. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570371/[Last accessed on February 15, 2024].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP